FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer By Ogkologos - July 11, 2025 303 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR Finding New Uses for Targeted Therapies for Cancer: Updates from the... November 9, 2023 EMA Recommends Granting Marketing Authorisation for Generic Abiraterone Acetate May 4, 2021 Longtime NPR Reporter Shares Diagnosis to Bring More Awareness to Metastatic... June 26, 2021 How People With Cancer Can Benefit From Online Therapy October 22, 2020 Load more HOT NEWS When Ovarian Cancer Returns, Surgery May Be a Good Choice for... Cancer in My Community: Providing Supportive Care in Serbia SIOG 2020: New Research in Caring for and Treating People With... Omission of Surgical Axillary Staging Noninferior To Sentinel Lymph Node Biopsy...
